These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12583823)

  • 21. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
    Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
    Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
    Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
    J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan.
    Lev-Chelouche D; Abu-Abeid S; Kollander Y; Meller I; Isakov J; Merimsky O; Klausner JM; Gutman M
    J Surg Oncol; 1999 Mar; 70(3):185-9. PubMed ID: 10102350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.
    Eggermont AM; ten Hagen TL
    Curr Oncol Rep; 2001 Jul; 3(4):359-67. PubMed ID: 11389822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of hyperthermic perfusion in the treatment of tumors of the extremities.
    Di Filippo F; Carlini S; Cavaliere F; Giannarelli D; Cavallero L; Moscarelli F; Aloe L; Cavaliere R
    Adv Exp Med Biol; 1990; 267():223-34. PubMed ID: 2088040
    [No Abstract]   [Full Text] [Related]  

  • 29. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
    Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
    Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU
    Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared.
    Cecchin D; Negri A; Frigo AC; Bui F; Zucchetta P; Bodanza V; Gregianin M; Campana LG; Rossi CR; Rastrelli M
    Eur J Surg Oncol; 2016 Dec; 42(12):1898-1905. PubMed ID: 27005884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Schlag PM; Kroon BB; Ben-Ari G; Lejeune FJ
    Cancer Treat Res; 1997; 91():189-203. PubMed ID: 9286497
    [No Abstract]   [Full Text] [Related]  

  • 36. Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation.
    Stamatiou D; Ioannou CV; Kontopodis N; Michelakis D; Perisinakis K; Lasithiotakis K; Zoras O
    J Surg Res; 2017 Jun; 213():147-157. PubMed ID: 28601307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors.
    Kettelhack C; Wickede Mv; Vogl T; Schneider U; Hohenberger P
    Cancer; 2002 Mar; 94(5):1557-64. PubMed ID: 11920514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
    Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
    Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current uses of isolated limb perfusion in the clinic and a model system for new strategies.
    Eggermont AM; de Wilt JH; ten Hagen TL
    Lancet Oncol; 2003 Jul; 4(7):429-37. PubMed ID: 12850194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
    Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS
    Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.